We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
44 hedge funds and large institutions have $46.7M invested in Esperion Therapeutics in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
0% more funds holding
Funds holding: 44 → 44 (0)
12% less capital invested
Capital invested by funds: $53.2M → $46.7M (-$6.49M)
Holders
44
Holders Change
–
Holders Change %
0%
% of All Funds
1.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
19
Reduced
16
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$3.07M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.76M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.49M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$910K |
| 5 |
Millennium Management
New York
|
+$873K |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.88M |
| 2 |
Morgan Stanley
New York
|
-$2.17M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$1.65M |
| 4 |
O
OrbiMed
New York
|
-$1.15M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.04M |
